close
MENU
Margin Call
5 mins to read

Ryman looks like a classic value trap

ANALYSIS: If you think a company must be ‘value’ because its share price is down 50%, look again.

Ryman was clearly an in-favour NZX listed business as 2020 began.

It is a fact that Ryman Healthcare enjoyed a stellar run from 2009 to 2020, up nearly 1800% from 85c to $16. It can also be readily assumed that a bunch of investors made good money from holding Ryman over parts of this 10-year period. Sustained periods of strong returns that create investors

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace

Yearly Premium Online Subscription

NZ$499.00 / yearly

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$350+GST / monthly

$35 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$600+GST / monthly

$30 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1250+GST / monthly

$25 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$1875+GST / monthly

$18.75 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Already have an account? Login
Stephen Bennie Tue, 07 Feb 2023
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Ryman looks like a classic value trap
Margin Call,
97528
true